Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin

[1]  M. Jacobs,et al.  Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin , 1994, Antimicrobial Agents and Chemotherapy.

[2]  S. Brown,et al.  In-vitro activity of cefepime and other antimicrobials: survey of European isolates. , 1993, The Journal of antimicrobial chemotherapy.

[3]  A. Ehrhardt,et al.  β-Lactam resistance amongst Enterobacter species , 1993 .

[4]  D. Livermore,et al.  Effects of β-lactamase induciblilty and derepression on the activity of cefepime and cefpirome against Gram-negative bacteria , 1993 .

[5]  R. Jones,et al.  Antimicrobial activity of FK-037 against class I beta-lactamase producing species resistant to ceftazidime: a multi-laboratory clinical isolate sample. , 1993, The Journal of antimicrobial chemotherapy.

[6]  P. Murray,et al.  Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime , 1993, Antimicrobial Agents and Chemotherapy.

[7]  H. Neu,et al.  In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin , 1993, Antimicrobial Agents and Chemotherapy.

[8]  B. Foleno,et al.  In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin , 1993, Antimicrobial Agents and Chemotherapy.

[9]  Y. Matsumoto,et al.  In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin. , 1993, The Journal of antibiotics.

[10]  R. Jones,et al.  Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers. , 1991, Diagnostic microbiology and infectious disease.

[11]  I. Phillips,et al.  Comparative in vitro activity of cefpirome and cefepime, two new cephalosporins , 1990, European Journal of Clinical Microbiology and Infectious Diseases.

[12]  F. J. DeOrio,et al.  Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels , 1989, Antimicrobial Agents and Chemotherapy.

[13]  R. Jones,et al.  In-vitro activity of FK-037, a new parenteral cephalosporin. , 1994, The Journal of antimicrobial chemotherapy.

[14]  N. Rolando,et al.  The penetration of imipenem/cilastatin into ascitic fluid in patients with chronic liver disease. , 1994, The Journal of antimicrobial chemotherapy.

[15]  R. Hancock,et al.  Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins. , 1992, The Journal of antimicrobial chemotherapy.

[16]  R. Jones,et al.  Activity of cefepime (BMY-28142) and cefpirome (HR 810) against gram-negative bacilli resistant to cefotaxime or ceftazidime. , 1989, The Journal of antimicrobial chemotherapy.